Overview

3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection

Status:
Completed

Trial end date:
2016-01-05

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate durability of SVR in chronic HCV patients who achieved SVR in the previous study with TMC435-containing regimen and time for resistance associated mutations to return to baseline in chronic HCV patients who did not achieve SVR in the previous study with TMC435-containing regimen.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen R&D Ireland

Treatments:

Simeprevir